Icon

ZOLPIMIST (nda022196)- (5MG/SPRAY)

ZOLPIDEM TARTRATE AYTU
5MG/SPRAY
No Yes
2032-Aug-07 Expired
None None
None No
ZOLPIMIST is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem tartrate has been shown to decrease sleep latency for up to 35 days in controlled clinical studies.
0 0 0
Total Other Developers None
Drugs with Suitability No
5MG/SPRAY ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.